GSK Australia has a new immunisation resource for Aboriginal and Torres Strait Islanders this month to encourage families to be proactive when it comes to immunising themselves and their children against preventable diseases.
These press releases are intended for business journalists and analysts/investors
GSK Australia is a recipient of a grant through of the Federal Government’s Manufacturing Transition Programme worth AUD$1 million. Funding will support GSK’s advanced manufacturing expansion plans at its Boronia site which focus on new product development using innovative “Blow-Fill-Seal” (BFS) technology.
GlaxoSmithKline (GSK) Australia reported to the Australian Securities and Investment Commission (ASIC) sales revenue of $906m in 2014 for its continuing operations and a profit before tax of $22m.
Nominations for GSK’s Award for Research Excellence (ARE) open today for the 35th year running. The longstanding award acknowledges outstanding Australian researchers and their work and is accompanied by an $80K grant to assist the winner on their research journey.
GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia and available for private sale, is no longer available for the remainder of the 2015 influenza season due to high levels of demand.
In 2014, GSK Australia made payments totalling $3,466,951 to healthcare professionals (HCPs) and health-related organisations (HCOs) for grants, sponsorships and consultancy fees related to chairing and speaking at meetings, assistance with training and participation in advisory boards.
Learn more about how we are making our vaccines more accessible in developing countries
More children from the world’s poorest countries are being vaccinated against more diseases than ever before.
GSK provides £50,000 donation to Save the Children to support relief efforts following Tropical Cyclone Pam.
GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis has completed today.
MELBOURNE, AUSTRALIA and MUMBAI, INDIA, 3 March, 2015 - GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE:524715, “Sun Pharma”) today announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.